Economic considerations in the use of the platelet GP IIb/IIIa inhibitor abciximab in percutaneous coronary intervention.
Platelet GP IIb/IIIa receptors : the new target in cardiovascuar medicine. International Symposium. Rhodes, GRC, 1998/05/28.
Multiple, large-scale randomized clinical trials have shown that platelet glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitor treatment in patients undergoing percutaneous coronary intervention is safe and effective in reducing the occurrence of adverse ischaemic clinical outcomes.
Despite these compelling data, economic considerations have hindered adoption of such treatment as the standard of care.
Available economic studies from clinical trials of the GP IIb/IIIa inhibitor abciximab indicate that, in broad patient populations, treatment with this agent does not reduce net early (e.g. 30-day) hospital direct costs despite improved outcomes.
In these broad patient groups, however, the savings associated with the clinical efficacy of abciximab does substantially defray the cost of the drug.
In addition, there is evidence that abciximab use may be associated with an overall net 6-month cost savings in high-risk subpopulations, such as patients with acute coronary syndromes.
Although abciximab treatment does not reduce overall in-hospital direct costs, neither do other highly effective therapies.
The question relevant to clinical practice is how cost-effective is GP IIb/IIIa receptor blockade in comparison with other frequently used, accepted therapeutic modalities.
Such analyses indicate that abciximab is cost-effective, with the cost-per-life-year-saved favourable compared with other standard-of-care treatments. (...)
Mots-clés Pascal : Dilatation instrumentale, Artère coronaire, Abciximab, Thrombocyte, Glycoprotéine, Récepteur biologique, Analyse coût efficacité, Economie santé, Chimiothérapie, Traitement, Pronostic, Homme, Inhibiteur thromboagrégation, Traitement instrumental, Inhibiteur
Mots-clés Pascal anglais : Instrumental dilatation, Coronary artery, Abciximab, Platelet, Glycoprotein, Biological receptor, Cost efficiency analysis, Health economy, Chemotherapy, Treatment, Prognosis, Human, Antiplatelet agent, Instrumentation therapy, Inhibitor
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0253843
Code Inist : 002B02G. Création : 16/11/1999.